GROUPE EUROMEDIS EO 2
Laboratoires Euromedis Société anonyme manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, microperfusionists; infusion and transfusion services, catheters, a… Read more
GROUPE EUROMEDIS EO 2 (61R) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GROUPE EUROMEDIS EO 2 (61R) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GROUPE EUROMEDIS EO 2 - Net Assets Trend (None–None)
This chart illustrates how GROUPE EUROMEDIS EO 2's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GROUPE EUROMEDIS EO 2 (None–None)
The table below shows the annual net assets of GROUPE EUROMEDIS EO 2 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GROUPE EUROMEDIS EO 2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GROUPE EUROMEDIS EO 2 Competitors by Market Cap
The table below lists competitors of GROUPE EUROMEDIS EO 2 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LIGHT UP TOTAL SOLUTION COMPANY LIMITED
BK:LTS
|
$4.69 Million |
|
Aneka Jaringan Holdings Bhd
KLSE:0226
|
$4.69 Million |
|
Pertama Digital Berhad
KLSE:8532
|
$4.69 Million |
|
Hoa An JSC
VN:DHA
|
$4.69 Million |
|
Tony G Co-Investment Holdings Ltd
PINK:BGRDF
|
$4.69 Million |
|
PHI Group Inc
PINK:PHIL
|
$4.69 Million |
|
Hanover House Inc.
PINK:HHSE
|
$4.69 Million |
|
Diamond Estates Wines & Spirits Inc
PINK:DWWEF
|
$4.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GROUPE EUROMEDIS EO 2's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GROUPE EUROMEDIS EO 2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GROUPE EUROMEDIS EO 2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GROUPE EUROMEDIS EO 2's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,192,244,105,699
- Average return on equity (ROE) among peers: -83.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GROUPE EUROMEDIS EO 2 (61R) | €- | N/A | N/A | $4.69 Million |
| KIMIA FARMA -B- (HQP) | $5.89 Trillion | 5.13% | 1.93x | $78.59 Million |
| Asker Healthcare Group AB (I88) | $3.50 Billion | 10.28% | 2.75x | $1.37 Billion |
| Paragon Care Limited (PXS) | $18.21 Million | 5.96% | 0.48x | $52.86 Million |
| TELES Informationstechnologien AG (TLIK) | $379.23K | -446.97% | 3.69x | $801.14K |
| Sinopharm Group Co. Ltd (X2S) | $68.28 Billion | 8.55% | 2.45x | $3.27 Billion |